IN2014MN00139A - - Google Patents
Download PDFInfo
- Publication number
- IN2014MN00139A IN2014MN00139A IN139MUN2014A IN2014MN00139A IN 2014MN00139 A IN2014MN00139 A IN 2014MN00139A IN 139MUN2014 A IN139MUN2014 A IN 139MUN2014A IN 2014MN00139 A IN2014MN00139 A IN 2014MN00139A
- Authority
- IN
- India
- Prior art keywords
- endoxifen
- formulations
- diseases
- breast
- agents
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/10—Oxygen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyrane Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86042006P | 2006-11-21 | 2006-11-21 | |
| US86078806P | 2006-11-22 | 2006-11-22 | |
| PCT/US2007/085443 WO2008070463A2 (en) | 2006-11-21 | 2007-11-21 | Endoxifen methods and compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014MN00139A true IN2014MN00139A (lt) | 2015-06-19 |
Family
ID=39492975
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN139MUN2014 IN2014MN00139A (lt) | 2006-11-21 | 2007-11-21 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US9333190B2 (lt) |
| EP (1) | EP2101731B1 (lt) |
| JP (1) | JP2010510327A (lt) |
| CA (1) | CA2669913C (lt) |
| DK (1) | DK2101731T3 (lt) |
| ES (1) | ES2665917T3 (lt) |
| HU (1) | HUE037109T2 (lt) |
| IN (1) | IN2014MN00139A (lt) |
| PL (1) | PL2101731T3 (lt) |
| PT (1) | PT2101731T (lt) |
| WO (1) | WO2008070463A2 (lt) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090291134A1 (en) * | 2006-11-21 | 2009-11-26 | Jina Pharmaceuticals, Inc. | Endoxifen methods and compositions in the treatment of psychiatric and neurodegenerative diseases |
| DK2101731T3 (en) | 2006-11-21 | 2018-04-16 | Jina Pharmaceuticals Inc | ENDOXIFEN FOR USING CANCER TREATMENT |
| EP3202420B1 (en) * | 2008-12-11 | 2020-03-04 | Besins Healthcare Luxembourg SARL | Transdermal pharmaceutical compositions comprising a serm |
| PL2701720T3 (pl) | 2011-04-28 | 2017-12-29 | Oncopeptides Ab | Liofilizowany preparat cytotoksycznych dipeptydów |
| EP2668945A1 (de) | 2012-06-01 | 2013-12-04 | Bayer Technology Services GmbH | Genotyp- bzw. Phänotyp-basierte Arzeimittelformulierungen |
| SI2928463T1 (sl) * | 2012-10-26 | 2020-03-31 | Oncopeptides Ab | Liofilizirani pripravki melfalan flufenamida |
| CA2992282A1 (en) * | 2015-07-14 | 2017-01-19 | Atossa Genetics Inc. | Transpapillary methods and compositions for treating breast disorders |
| DE102015222031A1 (de) | 2015-11-10 | 2017-05-11 | Robert Bosch Gesellschaft Für Medizinische Forschung Mbh | Synthese von (Z)-Endoxifenhydrochlorid |
| US20170304232A1 (en) * | 2016-04-20 | 2017-10-26 | Northwestern University | Endoxifen For Local Transdermal Therapy To The Breast |
| CA3073836A1 (en) | 2017-09-11 | 2019-03-14 | Atossa Therapeutics, Inc. | Methods for making and using endoxifen |
| CA3074302A1 (en) * | 2017-09-11 | 2019-03-14 | Atossa Therapeutics, Inc. | Topical compositions and methods for treatment |
| JP2022538911A (ja) * | 2019-07-03 | 2022-09-06 | アトッサ・セラピューティクス・インコーポレイテッド | エンドキシフェンの徐放性組成物 |
| BR112022020320A2 (pt) | 2020-04-10 | 2022-12-13 | Jina Pharmaceuticals Inc | Método para manter uma concentração terapeuticamente eficaz de endoxifeno para tratamento de um paciente com distúrbio bipolar i |
| WO2022197988A1 (en) * | 2021-03-18 | 2022-09-22 | National Taiwan University | Lipid-based nanoparticle delivery system for hydrophilic charged compound |
| CA3241735A1 (en) | 2022-01-12 | 2023-07-20 | Yao-Lin Sun | Compositions of (z)-endoxifen and methods of enrichment thereof |
| WO2023211939A1 (en) * | 2022-04-26 | 2023-11-02 | Atossa Therapeutics, Inc. | High dose endoxifen formulations and methods of use |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2817157A1 (de) * | 1978-04-17 | 1979-10-25 | Schering Ag | Verwendung von antioestrogenen und antigonadotrop wirkenden antiandrogenen zur prophylaxe und therapie der prostatahyperplasie |
| US6290991B1 (en) * | 1994-12-02 | 2001-09-18 | Quandrant Holdings Cambridge Limited | Solid dose delivery vehicle and methods of making same |
| EP1138319A3 (en) * | 1994-08-04 | 2003-03-19 | Elan Drug Delivery Limited | Solid delivery systems for controlled release of molecules incorporated therein and methods of making same |
| EP0935415B1 (en) * | 1996-05-01 | 2006-11-22 | Imarx Pharmaceutical Corp. | In vitro methods for delivering nucleic acids into a cell |
| US6090407A (en) * | 1997-09-23 | 2000-07-18 | Research Development Foundation | Small particle liposome aerosols for delivery of anti-cancer drugs |
| US7968532B2 (en) | 2003-12-15 | 2011-06-28 | Besins Healthcare Luxembourg | Treatment of gynecomastia with 4-hydroxy tamoxifen |
| DK2076244T3 (en) | 2006-10-10 | 2017-02-27 | Jina Pharmaceuticals Inc | Aqueous systems for the preparation of lipid-based pharmaceutical compounds; compositions, methods and uses thereof |
| WO2008048194A1 (en) | 2006-10-20 | 2008-04-24 | Yesilogluj Aysegul Yildiz | Use of the protein kinase c inhibitor tamoxifen for the treatment of bipolar disorder |
| CA2669355C (en) | 2006-11-06 | 2012-10-30 | Jina Pharmaceuticals, Inc. | Guggulphospholipid methods and compositions |
| US20090291134A1 (en) | 2006-11-21 | 2009-11-26 | Jina Pharmaceuticals, Inc. | Endoxifen methods and compositions in the treatment of psychiatric and neurodegenerative diseases |
| DK2101731T3 (en) | 2006-11-21 | 2018-04-16 | Jina Pharmaceuticals Inc | ENDOXIFEN FOR USING CANCER TREATMENT |
| JP5720881B2 (ja) | 2011-01-31 | 2015-05-20 | 東芝ライテック株式会社 | Ｌｅｄランプ点灯装置および照明装置 |
-
2007
- 2007-11-21 DK DK07871563.8T patent/DK2101731T3/en active
- 2007-11-21 ES ES07871563.8T patent/ES2665917T3/es active Active
- 2007-11-21 PT PT78715638T patent/PT2101731T/pt unknown
- 2007-11-21 IN IN139MUN2014 patent/IN2014MN00139A/en unknown
- 2007-11-21 WO PCT/US2007/085443 patent/WO2008070463A2/en active Application Filing
- 2007-11-21 EP EP07871563.8A patent/EP2101731B1/en not_active Revoked
- 2007-11-21 US US12/515,261 patent/US9333190B2/en active Active
- 2007-11-21 CA CA2669913A patent/CA2669913C/en active Active
- 2007-11-21 PL PL07871563T patent/PL2101731T3/pl unknown
- 2007-11-21 JP JP2009538518A patent/JP2010510327A/ja active Pending
- 2007-11-21 HU HUE07871563A patent/HUE037109T2/hu unknown
-
2016
- 2016-04-27 US US15/139,687 patent/US10376479B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2008070463A3 (en) | 2008-11-06 |
| PL2101731T3 (pl) | 2018-07-31 |
| EP2101731A4 (en) | 2011-04-20 |
| DK2101731T3 (en) | 2018-04-16 |
| WO2008070463A2 (en) | 2008-06-12 |
| US10376479B2 (en) | 2019-08-13 |
| US20100112041A1 (en) | 2010-05-06 |
| EP2101731B1 (en) | 2018-01-31 |
| CA2669913A1 (en) | 2008-06-12 |
| US9333190B2 (en) | 2016-05-10 |
| HUE037109T2 (hu) | 2018-08-28 |
| ES2665917T3 (es) | 2018-04-30 |
| WO2008070463A9 (en) | 2008-09-18 |
| JP2010510327A (ja) | 2010-04-02 |
| EP2101731A2 (en) | 2009-09-23 |
| PT2101731T (pt) | 2018-04-18 |
| US20160346230A1 (en) | 2016-12-01 |
| CA2669913C (en) | 2012-09-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014MN00139A (lt) | ||
| MY155649A (en) | Pyridyloxyindoles inhibitors of vegf-r2 and use thereof for treatment of disease | |
| EA201690265A3 (ru) | Фармацевтические композиции, содержащие замещенные ациланилиды | |
| PH12014501560A1 (en) | Carbamate compounds and of making and using same | |
| MX2010014233A (es) | Compuestos quimicos 251. | |
| UA107783C2 (en) | Isoindoline compounds for use in treating cancer | |
| TN2012000143A1 (en) | Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof | |
| AU2011338389A8 (en) | Bicyclic compounds as Pim inhibitors | |
| MX2008011978A (es) | Tratamiento del cancer de seno negativo al triple receptor. | |
| MY198422A (en) | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same | |
| MX2007002398A (es) | Nuevas composiciones farmaceuticas para el tratamiento de cancer. | |
| MX337575B (es) | Compuestos de sulfona y métodos para lafabricación y uso de éstos. | |
| IL206563A (en) | A preparation or drug containing a suspension of blood cells that contain asparaginase for use in the treatment of pancreatic cancer | |
| SG155921A1 (en) | Bicyclic amides as kinase inhibitors | |
| MX2009006704A (es) | Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa. | |
| UA86614C2 (ru) | Соединение, которое имеет активность ингибитора киназ, фармацевтическая композиция, которая включает указанное соединение, и их применение для приготовления лекарственного препарата | |
| MY179527A (en) | Catecholamine derivatives useful for the treatment of parkinson's disease | |
| UA104988C2 (uk) | Похідні піроніндолу та спосіб їх отримання | |
| TW200628473A (en) | Novel heterocycles | |
| WO2007121088A3 (en) | Combinations of therapeutic agents for treating cancer | |
| MX2009006327A (es) | Compuestos heterociclicos y metodos de uso de los mismos. | |
| EA201291089A1 (ru) | Способ получения фармацевтических препаратов, предназначенных для перорального введения, содержащих один или более активных ингредиентов, и содержащих их композиций | |
| GB0620385D0 (en) | Novel compounds | |
| GEP201606513B (en) | Pharmaceutical compositions for the treatment of cancer and other diseases or disorders | |
| PH12020500099A1 (en) | Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a cyclin d kinase inhibitor |